Pharmaceutical compositions comprising zolmitriptan
AssigneeMapLight Therapeutics, Inc.
InventorsMichael WOOD, James LILLIE
Life of this patent
Estimating the term…
Abstract
Provided herein are oral compositions comprising zolmitriptan, and methods of use thereof e.g., for the treatment of the symptoms of autism spectrum disorder, and the treatment of aggression in patients with dementia.
Claims57
An oral composition for treating the symptoms of autism spectrum disorder, wherein the composition comprises from about 7.5 mg to about 90 mg of zolmitriptan, or a pharmaceutical acceptable salt thereof, and the oral administration of the composition provides a therapeutically effective plasma concentration of zolmitriptan for a period of at least 8 hours.
An oral composition of zolmitriptan, or a pharmaceutically acceptable salt thereof for treating the symptoms of autism spectrum disorder providing a modified release profile,
- wherein the composition when dissolution tested using United States Pharmacopoeia Apparatus II (paddles @ 50 rpm) in 900 mL of 0.1N HCl at 37° C. exhibits a zolmitriptan release profile substantially corresponding to the following pattern:
- from about 20%-40% of the total zolmitriptan is released after about 15 minutes;
- after 4 h about 40%-75% of the total zolmitriptan is released;
- and
- after 8 h about 75%-90% of the total zolmitriptan is released.
A composition for treating the symptoms of autism spectrum disorder, wherein the composition comprises zolmitriptan, or a pharmaceutically acceptable salt thereof, wherein the oral administration of the composition provides an AUC0-24h of about 40 ng·h/mL to about 300 ng·h/mL to treat the symptoms of autism spectrum disorder.
Dependencies are inferred from the claim text.